Brainchild Bio plans to launch a pivotal Phase 2 clinical trial to test its investigational cell therapy BCB-276 in patients with diffuse intrinsic pontine…
News
The U.S. Food and Drug Administration (FDA) has agreed to review Verastem Oncology’s application seeking approval of a combination of avutometinib and defactinib for…
Minimal residual disease or MRD — defined as a very small number of cancer cells that remain in the body during or after treatment —…
Treatment with the antipsychotic medication clozapine may increase the risk of blood cancers, but their overall likelihood is still low in people taking the drug,…
Fluorescent imaging can safely help surgeons find and remove small tumors in the pancreas, according to a recent report. The case study describes how the…
Chimerix has submitted an application asking the U.S. Food and Drug Administration (FDA) to approve its oral therapy dordaviprone as a treatment for recurrent…
Adding elraglusib, a small molecule being developed by Actuate Therapeutics, to standard chemotherapy with gemcitabine and nab-paclitaxel (GnP) as a first-line treatment for metastatic…
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to the anti-cancer agent THIO as a potential treatment for an uncommon…
A person’s microbiome, or the collection of all microorganisms that live in the gut, can enhance the body’s antitumor response and lead to better treatment…
Most people with relapsed or refractory multiple myeloma (RRMM) given the cell therapy anitocabtagene autoleucel — known as anito-cel — in a Phase 2…
